KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Amgen (AMGN) Research & Development (2016 - 2026)

Amgen has reported Research & Development over the past 18 years, most recently at $1.7 billion for Q1 2026.

  • For Q1 2026, Research & Development rose 15.68% year-over-year to $1.7 billion; the TTM value through Mar 2026 reached $7.5 billion, up 22.89%, while the annual FY2025 figure was $7.3 billion, 21.93% up from the prior year.
  • Research & Development for Q1 2026 was $1.7 billion at Amgen, down from $2.1 billion in the prior quarter.
  • Over five years, Research & Development peaked at $2.1 billion in Q4 2025 and troughed at $959.0 million in Q1 2022.
  • A 5-year average of $1.4 billion and a median of $1.4 billion in 2024 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: decreased 21.8% in 2022 and later surged 34.38% in 2024.
  • Year by year, Research & Development stood at $1.3 billion in 2022, then increased by 15.86% to $1.5 billion in 2023, then increased by 12.39% to $1.7 billion in 2024, then grew by 24.25% to $2.1 billion in 2025, then decreased by 19.75% to $1.7 billion in 2026.
  • Business Quant data shows Research & Development for AMGN at $1.7 billion in Q1 2026, $2.1 billion in Q4 2025, and $1.9 billion in Q3 2025.